Commercialanti-CD19 CART cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

Autor: Sesques, P, Ferrant, E, Safar, V, Wallet, F, Tordo, J, Dhomps, A, Karlin, L, Brisou, G, Vercasson, M, Hospital-Gustem, C, Schwiertz, V, Ranchon, F, Rioufol, C, Choquet, M, Sujobert, P, Ghergus, D, Bouafia, F, Golfier, C, Lequeu, H, Lazareth, A, Novelli, S, Devic, P, Glehen, AT, Viel, S, Venet, F, Mialou, V, Hequet, O, Chauchet, A, Arkam, Y, Nicolas-Virelizier, E, Peyrade, F, Cavalieri, D, Ader, F, Ghesquieres, H, Salles, G, Bachy, E
Rok vydání: 2020
Zdroj: AMERICAN JOURNAL OF HEMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
ISSN: 0361-8609
Popis: Two autologous anti-CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi-cel] and tisagenlecleucel [tisa-cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). We performed a retrospective study to evaluate patterns of use, efficacy and safety for axi-cel and tisa-cel. Data from 70 patients who underwent apheresis for commercial CAR T cells between January 2018 and November 2019 in our institution were retrospectively collected. Sixty-one patients were infused. The median age at infusion was 59 years old (range 27-75 years). The median number of prior therapies was 3 (range, 2-6). The overall response rates (ORRs) at 1 month and 3 months were 63% and 45%, respectively, with 48% and 39% achieving a complete response (CR), respectively. After a median follow-up after infusion of 5.7 months, the median progression-free survival (PFS) was 3.0 months (95% CI, 2.8-8.8 months), and the median overall survival (OS) was 11.8 months (95% CI, 6.0-12.6 months). In multivariate analysis, factors associated with poor PFS were the number of previous lines of treatment before CAR T cells (>= 4) (P= .010) and a C reactive protein (CRP) value >30 mg/L at the time of lymphodepletion (P 30 mg/L (P= .009). Cytokine release syndrome (CRS) of any grade occurred in 85% of patients, including 8% of patients with CRS of grade 3 or higher. Immune cell-associated neurotoxicity syndrome (ICANS) of any grade occurred in 28% of patients, including 10% of patients with ICANS of grade 3 or higher. Regarding efficacy and safety, no significant difference was found between axi-cel and tisa-cel. This analysis describes one of the largest real-life cohorts of patients treated with axi-cel and tisa-cel for R/R aggressive B cell lymphoma in Europe.
Databáze: OpenAIRE
Externí odkaz: